This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Trevena, Inc.

Drug Names(s): TRV130, TRV130A

Description: TRV130 is a novel, biased ligand that targets the mu-opioid receptor to optimize analgesia while minimizing mu opioid receptor-mediated side effects such as respiratory suppression and constipation. As a biased ligand, TRV130 activates the G-protein signaling pathway mediated by the mu-opioid receptor while antagonizing the beta-arrestin pathway.

Oliceridine News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug